Correction: Higher phosphorylated tau levels predict cognitive decline and amyloid-related imaging abnormalities during lecanemab treatment: clinical practice data

Correction: Alz Res Therapy 17, 251 (2025)

https://doi.org/10.1186/s13195-025-01912-6

Following publication of the original article [1], the 95%CI “19.98 (2.43-163.81.43.81)” and “18.39 (1.91-176.33.91.33)”of Models 4 and 5 for High ptau group in Table 3 were incorrect, and should have been “19.98 (2.43-163.81)” and “18.39 (1.91-176.33)”. The corrected Table 3 is given below.

Table 3.

Demographics and cognitive tests results of patients at baseline and follow-up, who initiated lecanemab treatment

	No. of ARIA cases/patients	Model 1 OR (95%CI)	Model 2 OR (95%CI)	Model 3 OR (95%CI)	Model 4 OR (95%CI)	Model 5 OR (95%CI)
Low ptau group	2/36	1.00 (reference)	1.00 (reference)	1.00 (reference)	1.00 (reference)	1.00 (reference)
High ptau group	10/34	8.69 (1.62-46.43)	7.83 (1.44-42.59)	7.79 (1.43-42.45)	19.98 (2.43-163.81)	18.39 (1.91-176.33)

Abbreviations: CI confidence interval, OR odds ratio, ptau phosphorylated tau

Model 1 was adjusted for age and sex

Model 2 was adjusted for age, sex, and APOE4 status

Models 3, 4, and 5 were adjusted for global clinical dementia rating score, amyloid PET centiloid value, number of microbleeds on baseline MRI in addition to the covarites in Model 2, respectively

The original article [1] has been corrected.